Bone hydroxyapatite (HA) (HA)

Bone hydroxyapatite is the primary inorganic component of the skeletal matrix, consisting of a crystalline lattice of calcium and phosphate with the chemical formula Ca10(PO4)6(OH)2 [1]. In regions of increased bone turnover, such as those undergoing active remodeling or affected by metastatic disease, the mineral surface becomes more accessible and provides a high-affinity substrate for various therapeutic agents [2]. This target is primarily utilized by bisphosphonates, which bind to the hydroxyapatite crystals to inhibit osteoclast-mediated bone resorption, and by bone-seeking radiopharmaceuticals that deliver targeted radiation to skeletal lesions [3]. The interaction is characterized by the strong affinity of phosphonate groups or divalent cations for the calcium sites within the crystal lattice [4]. Consequently, bone hydroxyapatite serves as both a structural scaffold and a pharmacological anchor for treating metabolic bone disorders and bone-resident malignancies [5]. Sources: [1] PubChem (CID 14781); [2] StatPearls, Bisphosphonates; [3] NCI Drug Dictionary, Radium Ra 223 dichloride; [4] Journal of Nuclear Medicine, Mechanism of 99mTc-MDP uptake; [5] Bone, Hydroxyapatite as a drug delivery system.

Other names

HydroxyapatiteHydroxylapatiteCalcium hydroxyapatiteBone mineralCrystalline bone mineralBone hydroxyapatite in regions of increased bone turnover

Drugs target bone hydroxyapatite through high-affinity chelation or ionic binding to the crystal surface, particularly at sites of active remodeling where the mineral is exposed. Bisphosphonates bind to the mineral and are subsequently internalized by osteoclasts during resorption, where they inhibit enzymes like farnesyl pyrophosphate synthase (FPPS), leading to osteoclast apoptosis and reduced bone breakdown [1, 2]. Radiopharmaceuticals mimic calcium or use phosphonate ligands to deliver localized ionizing radiation (alpha or beta particles) directly to the mineralized matrix in areas of high turnover, such as osteoblastic metastases [3, 4].